High-level gain of mesenchymal-epithelial transition factor (MET) copy number using next-generation sequencing as a predictive biomarker for MET inhibitor efficacy.

Wu, Shibo; Li, Guodong; Zhao, Xin; Xiang, Jianxing; Lizaso, Analyn; Ye, Junyi; Shi, Chunlei; Chen, Lingxiang

Wu, Shibo; Li, Guodong; Zhao, Xin; Xiang, Jianxing; Lizaso, Analyn; Ye, Junyi; Shi, Chunlei; Chen, Lingxiang.

Affiliation

Wu S; Department of Respiratory Medicine, Lihuili Hospital, Ningbo Medical Center, Ningbo, China.
Li G; Department of Interventional Therapy, Fudan University Shanghai Cancer Center, Shanghai China.
Zhao X; Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiang J; Burning Rock Biotech, Guangzhou, China.
Lizaso A; Burning Rock Biotech, Guangzhou, China.
Ye J; Burning Rock Biotech, Guangzhou, China.
Shi C; Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Chen L; Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.

Ann Transl Med ; 8(11): 685, 2020 Jun.

Article de En | MEDLINE | ID: mdl-32617305

Mots clés

Mesenchymal-epithelial transition factor amplification (MET amplification); crizotinib; mesenchymal-epithelial transition factor copy number gain (MET CN gain); mesenchymal-epithelial transition factor tyrosine kinase inhibitor (MET TKI); predictive biomarker

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies / Risk_factors_studies Langue: En Journal: Ann Transl Med Année: 2020 Type de document: Article Pays d'affiliation: Chine Pays de publication: Chine

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google